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1. Introduction
The treatment of neurological disorders represents a critical issue in clinical research, since
no complete recovery of patients can be achieved with actual therapeutic means, despite
symptomatic improvements. Indeed, whereas restricted brain areas still house cells compe‐
tent to generate newborn neurons in adulthood, those neural stem cells are present in re‐
stricted amounts. Moreover, this limited neurogenesis does not seem to be sufficient to
enable neuronal regeneration in cases of traumatic, ischemic or degenerative lesions of the
central nervous system. Therefore, other sources of neural cells have to be considered in a
cell therapy objective.
Stem  cells  are  characterized  as  cells  endowed  with  continuous  self-renewal  ability  and
pluri- or multipotentiality, and could consequently give rise to a wide panel of cell types.
Non-germinal stem cells  are classified into different categories:  (1)  Embryonic stem cells
(ES) are found in the inner cell mass of blastocyst and are pluripotent stem cells that can
generate any mature cell  of  each of the three germ layers;  (2)  Induced pluripotent stem
cells  (iPS)  are adult  somatic  cells  that  are reprogrammed into pluripotent cells  with ES-
like abilities; (3) Somatic stem cells are tissue-specific and more restricted than ES cells in
terms of differentiation capabilities. They can be isolated from various fetal and adult tis‐
sues,  which make them an attractive  supply  of  material  for  cell  therapy.  Indeed,  while
neurons have already been successfully generated from ES cells [1] or iPS cells [2, 3], the
use of adult somatic stem cells definitely remain of significant interest regarding technical,
ethical and immunological issues concerning cell transplantation for brain diseases. In this
© 2013 Neirinckx et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
regard, mesenchymal stem cells (MSCs) and neural crest-derived stem cells (NCSCs) that
can be  found in  various locations of  the  adult  organism (and even in  perinatal  tissues)
represent an important source of easily-accessible multipotent cells to use in a cell therapy
purpose.
In this chapter, we will describe the major features of MSCs and NCSCs isolated from five
different tissues, which constitute the main exploited and accessible sources for cell isolation
in an objective of cell therapy protocols for neurological disorders (Figure 1). Moreover, we
will detail the multiple ways they can generate neuron-like cells in vitro. Indeed, numerous
culture conditions and differentiation protocols do exist and are demonstrated as efficient,
supporting the fact that neural differentiation can occur through different cellular signaling
mechanisms. Therefore, we will review the various signaling pathways that could trigger
the neural fate adoption of MSCs and NCSCs, and the related cell-based therapy experi‐
ments that have been done downstream.
2. Different types of mesenchymal stem cells
Mesenchymal stem cells (MSCs) are plastic-adherent, fibroblast-like cells, which are conven‐
tionally able to self-renew and differentiate into tissues of the mesodermic lineage, such as
bone, adipose tissue and cartilage. Whereas those cells have traditionally been isolated from
bone marrow stroma, many reports have now described the presence of MSCs in a variety
of fetal, perinatal and adult tissues, including peripheral blood, umbilical cord Wharton’s
Jelly and blood, fetal liver and lungs, adipose tissue, skeletal muscles, amniotic fluid, syno‐
vium and circulatory system, where they work as supportive cells and maintain tissue ho‐
meostasis.
2.1. Bone marrow mesenchymal stem cells
The initial study of non-hematopoietic bone marrow (BM) cells was performed by Frieden‐
stein et al. in the late 80’s [4, 5]. After establishing single cell suspensions of BM, they
showed that those cells were able to generate colonies of adherent fibroblast-shaped cells
when cultured in vitro. They demonstrated that these colony-forming unit - fibroblasts
(CFU-F) presented the ability to undergo osteogenic differentiation [5, 6]. These bone mar‐
row mesenchymal stem cells (BM-MSCs) were then demonstrated as multipotent progeni‐
tors that were able to self-renew [7] and could differentiate into any cell of the mesodermic
lineage, like osteoblasts, chondrocytes, or adipocytes [8, 9]. More interestingly, it has been
showed that BM-MSCs were able to “trans-differentiate” into cells with endodermal or ecto‐
dermal characteristics [10], and particularly into neuron-like cells [11-15]. These stem cells
are therefore raising huge interest, since they represent a promising source of material for
cell therapy protocols, such as mesenchymal tissue engineering or neurological disorder
treatments as well.
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Figure 1. Mesenchymal and neural crest stem cells from different perinatal and adult tissues. The upper part describes
the presence of mesenchymal and/or neural crest stem cells in various adult tissue. The lower part describes cell fate
that have been demonstrated for each type of stem cells regarding the mesodermic, endodermic or ectodermic cell
lineage.
The main debate concerning BM-MSCs resides in the lack of exact phenotypic characteriza‐
tion, due to the absence of specific membrane markers and non-standardized culture meth‐
ods. Consequently, several groups described BM-MSCs with a wide variety of different
phenotypes: Verfaillie’s group described a rare population of cells in human BM stroma as
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mesodermal adult progenitor cells (MAPCs)[12, 16]; D’Ippolito and collaborators cultured
cells in low oxygen tension and characterized marrow isolated adult multilineage inducible
(MIAMI) cells [17, 18]; whereas a lot of other groups kept the mesenchymal stem cell con‐
cept as defined by Pittenger et al. [9].
In addition to the phenotypic differences of BM-MSCs which are inherent to culture settings,
it has been demonstrated that BM stroma was a mixed population of cells arising from dif‐
ferent embryonic lineages. Although adult BM-MSCs were commonly considered to be of
mesodermal origin (bone marrow mesenchymal stem cells) [19], several studies have shown
that some adult BM-MSCs derive from the embryonic neural crest [20-24] (see paragraph be‐
low). Hence, the different studies that are detailed below often describe BM-MSCs without
distinguishing mesenchymal and neural-crest derived cells.
2.2. Adipose tissue stem cells
Similarly to the main part of BM stroma, adipose tissue derives from mesodermic lineage
and contains stem cells able to differentiate into bone, cartilage, fat and muscle. Likewise,
adipose tissue mesenchymal stem cells (AT-MSCs) can adopt a neural-like phenotype [25,
26], which makes them another potential source of cells to use in replacement therapy.
2.3. Umbilical cord blood and Wharton’s jelly mesenchymal stem cells
Wharton’s jelly constitutes the gelatinous matrix of umbilical cord. Mainly composed of col‐
lagen fibers, proteoglycans and stromal cells, this tissue has also been described to enclose
mesenchymal cells endowed with stem cells properties (WJ-MSCs); They are easily cultured
and expanded in vitro, and are able to differentiate into a wide range of cell types, including
neural cells [27-29].
Whereas adult peripheral blood only contains a tiny number of MSCs, umbilical cord blood
is a richer source and allows to culture adherent MSCs more efficiently. These umbilical
cord blood MSCs (UCB-MSCs) are considered as a more primitive population, but can be
largely expanded and maintained in long term culture [30], and were described to be an os‐
teogenic, adipogenic, chondrogenic and even a neurogenic cell population [31-33]. Altogeth‐
er, these data confirmed umbilical cord as a new source of cells for cellular therapeutics for
stromal, bone, and, potentially, neural repair [34].
3. Different types of neural crest stem cells
During embryonic development of vertebrates, neural crest is specified at the border of the
neural plate and the non-neural ectoderm after gastrulation. During neurulation, the neural
folds both join at the dorsal midline to form the neural tube. Subsequently, neural crest cells
(NCC) from the roof plate of the neural tube undergo an epithelial to mesenchymal transi‐
tion (EMT), delaminating from the neuroectoderm. Those multipotent NCC then migrate to‐
wards different locations in the body where they differentiate into various cell types,
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including melanocytes, craniofacial cartilage and bone, smooth muscle, peripheral and en‐
teric neuron, and glia.
In the past few years, multipotent and self renewing neural crest stem cells (NCSCs) have
been described to persist in the adult organism. Those post-migratory NCSCs were found in
the gut [35], the skin [36-38], the cornea [39], the heart [40], the teeth [41, 42], the dorsal root
ganglion and the bone marrow [21, 22, 43]. As the skin, the teeth and the bone marrow con‐
stitute the most easily-accessible and available sources of NCSCs to use in therapy protocols,
we will describe those three tissues more precisely.
3.1. Bone marrow neural crest stem cells
Regarding the striking similarities of bone marrow stromal cells and embryonic NCSCs con‐
cerning their neural differentiation potential, the question of the presence of a neural crest-
derived cell subpopulation in bone marrow was raised. Indeed, the mesodermal origin of
bone marrow stromal cells was definitely queried since a study of Takashima et al. demon‐
strated that a first wave of mesenchymal stem cells in the embryo derives from the Sox1-
positive neuroepithelium through a neural crest stage [20].
Lately, convincing evidence for the subsistence of NCSCs in bone marrow emerged from
a study by Nagoshi et al. They isolated neural crest-derived cells from the bone marrow
using Wnt1-Cre/FloxedEGFP mice for  in vivo  fate  mapping.  Those cells  could be propa‐
gated in sphere cultures for a couple of passages.  A bit  more than 3% of these isolated
EGFP+  cells had the capacity to differentiate into neurons, glia,  and smooth muscle cells
(this  proportion  was  sustainably  increased  by  collagenase  treatment,  suggesting  their
tight contact with bone surface) [21, 22]. The same group used another transgenic mouse
(P0-Cre/FloxedEGFP) to isolate NCSCs among the bone marrow stromal cells,  and dem‐
onstrated their  ability  to  differentiate  into neural  crest  lineages  but  also into mesenchy‐
mal  lineages  such  as  adipocytes,  chondrocytes  and  osteocytes  [22].  Using  a  Wnt1-Cre/
FloxedLacZ transgenic mouse,  the group of Wislet-Gendebien generated neural-crest  de‐
rived clones  of  passage 5  bone marrow stromal  cells,  and compared them with mesen‐
chymal clones. They showed that the two types of populations were surprisingly similar
at the transcriptomic level and in terms of differentiation abilities, and that both of them
could  give  rise  to  neurons  [43].  Altogether,  the  different  results  about  bone  marrow
NCSCs  make  those  cells  as  exciting  as  their  MSCs  neighbors  in  a  context  of  therapy.
Moreover, their neural crest origin may confer them particular additional properties in a
perspective of nervous system repair.
3.2. Skin-derived neural crest stem cells
Using the same type of Wnt1-Cre reporter mice, the groups of Sieber-Blum and Toma identi‐
fied neural crest-derived stem cells in the facial skin of adult mice and humans [36, 37, 44,
45]. Those skin-derived precursors (SKPs) are located in the dermal papillae and in the hair
follicle, and are able to differentiate in vitro into neurons, smooth muscle cells, Schwann cells
and melanocytes.
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Other skin-derived NCSCs, termed epidermal NCSCs (EPI-NCSCs) were isolated from the
bulge region of whisker follicles. Similarly to SKPs, EPI-NCSCs can give rise to neurons,
smooth muscle cells, Schwann cells and melanocytes [37, 44, 46]. As an easy-accessible au‐
tologous source of highly multipotent stem cells, the skin and its SKPs and EPI-NCSCs are
of significant interest in cell therapy.
3.3. Dental neural crest stem cells
The dental pulp is the connective tissue that forms the inner part of the teeth, and contains
ondotoblasts which are responsible of dentin formation. Few years ago, a population of
stem cells has been identified in dental pulp, and is thought to arise from the embryonic cra‐
nial neural crest [47, 48]. These dental pulp stem cells (DP-SCs) are endowed with high pro‐
liferative potential, self-renewal ability and multi-lineage differentiation [42, 49], making
them an attractive tool for stem cell therapeutic strategies. Whereas the DP-SCs are isolated
from the adult teeth, the same type of stem cells can be found in the human exfoliated decid‐
uous teeth (SHED cells), identified as immature DP-SCs.
The properties of self-renewal and multi-lineage differentiation ability of all described stem
cells make them truly attractive candidates for cell therapy. Furthermore, they offer the non-
negligible advantage of being easily obtained without invasive method. Indeed, whereas
umbilical cord is usually intended to trash after birth and can rather be preserved in order to
collect cells, bone marrow aspiration, lipo-aspiration, or teeth extraction are non-heavy pro‐
cedures that are commonly performed in clinical context. Those procedures could even be
performed in patients when needed, allowing autologous grafts and avoiding immunologi‐
cal rejects. Additionally, the use of MSCs/NCSCs, from either adult origin or isolated from
umbilical cord, get round the ethical problems related to fetal cells use. Moreover, those cells
are supposed to be safer than embryonic stem cells or induced pluripotent stem cells in
terms of tumorigenicity and genomic modifications [24, 50].
4. Signaling pathways involved in neural differentiation of MSCs and
NCSCs
As already mentioned, a wide range of culture settings for MSCs/NCSCs neural differentia‐
tion were commonly experienced, with some of them giving rise to substantial results.
Hence, it can be inferred that MSCs/NCSCs can give rise to neuronal cells through the acti‐
vation/deactivation of many intracellular signaling pathways. In this chapter, we will focus
on the analysis of several differentiating protocols that highlighted specific signaling path‐
ways in neuronal fate decision. We will dissect those pathways from the ligand molecules to
the different cellular and molecular effectors that are involved within, up to the gene expres‐
sion modulation. We will then describe the different downstream effects experimentally ob‐
served after activation of those pathways, in the context of neural fate adoption by different
type of MSCs/NCSCs and summarized in Figure 2 and Table 1.
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4.1. Cyclic-adenosine-monophosphate and PKA signaling pathway
Cyclic-adenosine-monophosphate (cAMP) is a well-known intracellular messenger, which is
physiologically synthesized from adenosine-triphosphate by a membrane-anchored adenyl‐
yl cyclase, when this last is induced by an active G protein-coupled receptor. In the cyto‐
plasm, cAMP essentially activates the protein kinase A (PKA), which then reach the nucleus
where it supports the phosphorylation of a transcription factor (cAMP responsive element
binding protein, or CREB protein). Once phosphorylated, CREB protein binds CREB-bind‐
ing protein (CREBB protein or CBP), and with the support of different co-factors, join specif‐
ic DNA sequences and regulate the expression of different genes (coding for c-fos, brain
derived neurotrophic factor (BDNF)[51], or tyrosine hydroxylase (TH)[52]). The destruction
of intracellular cAMP is mediated by phosphodiesterases (PDE), which convert cAMP into
AMP, then regulating cAMP cytoplasmic concentrations. This cAMP-dependent pathway
has been demonstrated to be fundamental in embryonic development, neural cells survival
and other processes like long term memory and neuronal plasticity [53-55].
cAMP is frequently used in culture media to induce MSCs/NCSCs into neural lineage, as
well as other molecules which raise the intracellular cAMP levels. For example, forskolin ac‐
tivates adenylyl-cyclase, dibutyryl-cAMP (db-cAMP) and 3-isobutyl-1-methylxanthine
(IBMX) both act as inhibitors of phosphodiesterases, and 8-bromo-cAMP activates PKA and
is long-acting because of its resistance to degradation by phosphodiesterases.
The main cytoplasmic target of cAMP, which is the PKA, has effectively been demonstrated
to mediate neural differentiation. Wang et al. studied the impact of PKA activation on neu‐
rite outgrowth and on neural markers glial acidic fibrillary protein (GFAP) and neurofila‐
ment (NF) expression. They observed that the complete inactivation of this kinase led to a
total absence of neural differentiation in UCB-MSCs, while the level of phosphorylated
CREB was upregulated in forskolin-treated cells (this effect was inhibited in presence of
PKA inhibitor) [56]. The involvement of PKA in the neural differentiation of MSCs was also
confirmed by several others studies [57,58].
According to Lepski et al., neuronal differentiation of human BM-MSCs resulted from a spe‐
cific mechanism dependent upon the PKA pathway. Indeed, they demonstrated that the
presence of a PKA inhibitor in the induction medium impaired the differentiation process
(induced by IBMX, coupled with brain-derived neurotrophic factor (BDNF), see paragraph
3.4.), and that CREB was phosphorylated in differentiated MSCs [59]. Moreover, MSC-de‐
rived cells showed significant voltage-dependent ionic currents (Na+, K+ and Ca2+ currents).
Besides, UCB-MSCs were induced to neural outcome with db-cAMP and IBMX treatment,
which was demonstrated to be necessary and sufficient for neurite-like outgrowth and for
nuclear receptor related 1 protein (Nurr1) expression. Nurr1 is known to play a key role in
dopaminergic system maintenance. In addition, those data showed evidence for cAMP-
pathway control on differential phosphorylation of TH isoforms [60].
Lin et al. studied the ability of granulocyte-macrophage colony-stimulating-factor (GM-CSF)
to promote neural differentiation in BM-MSCs through the phosphorylation of CREB [61].
Indeed, GM-CSF-treated BM-MSCs expressed higher levels of neuron specific enolase (NSE)
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over time, whereas transiently increased nestin expression. In parallel, a substantial increase
of phosphorylated-CREB level was observed in the GM-CSF-treated BM-MSCs compared
with control (CREB levels were not different between the two groups), and that the kinetics
of this increase was consistent with the progress in neural differentiation.
Figure 2. Different signaling pathways are involved in neural differentiation of MSCs and NCSCs.Each pathway and
modulating substances are described in the text.
While cAMP pathway is supposed to be involved in neural differentiation of MSCs, its pre‐
cise role in this differentiation process still needs to be defined. Zhang et al. showed evi‐
dence for the involvement of cAMP in two differentially-regulated processes, which are
early transient neuron-like morphology changes, like cytoskeleton rearrangement, and later
neural markers expression associated with neuronal function, but demonstrated that cAMP-
treated BM-MSCs did not achieve complete differentiation [62]. Another hypothesis was
made by Rooney et al., who examined the effect of intracellular cAMP elevation on BM-
MSCs’ fate [63]. They demonstrated that forskolin and 8-bromo-cAMP induced a transient
increase in βIII-tubulin expression and changes in cell morphology, but no expression of
growth associated protein 43 (GAP-43) [64] was seen in the neural-like BM-MSCs, excluding
authentic neurite formation. They therefore concluded that this effect was mostly due to a
modification of culture conditions rather than in a differentiation process.
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Cell type Passage Pathways Inductionprotocol
Protocol
length
Neural
phenotype
Electro-
physiological
profile
Inhibitor Reference
1 UCB-MSCs ns
cAMP-PKA-
CREB Forskolin 1 to 7 days NF, GFAP No
H89,
U0126 [56]
2 BM-MSCs P12-P24
cAMP-PKA-
CREB, NT
1) EGF,
bFGF. 2)
cAMP,
IBMX, BDNF
1) 1 week.
2) 12 hours
NF-200, NFM,
NeuroD,
MAP2, NeuN,
GABA
Inward Na+
currents and
outward K+
currents
PKAi
fragment
6–22
amide
[59]
3 BM-MSCs P3-P6
cAMP-PKA-
CREB GM-CSF
6 to 96
hours
Nestin, NSE,
GFAP No No [61]
4 BM-MSCs P0? cAMP-PKA
Forskolin,
IBMX
1 hour to 2
days
βIII-tubulin,
GFAP, NSE No H89 [62]
5 BM-MSCs ns cAMP
Forskolin /
8-bromo-
cAMP
6 and 24
hours / 1
and 4 days
βIII-tubulin No No [63]
6 BM-MSCs ns NT, SHH
SHH, FGF8,
bFGF (+
BDNF)
12 days NeuN, TH, βIII-tubulin, DAT
Inward Na+
currents and
outward K+
currents
No [65, 66]
7 BM-MSCs P3-P8
cAMP, RA,
SHH
Forskolin,
SHH and/or
RA
2 days
Nestin, Sox2,
NSE, GFAP,
synapsin, ACh
Neuronal
resting
potential
No [67]
8 BM-MSCs P3-P5
cAMP, NT,
RA, SHH
1) bFGF,
Forskolin. 2)
Forskolin,
IBMX, RA,
SHH, BDNF
7 days
GATA3, Sox10,
GluR4, Irx2,
calretinin,
MAP2, NeuN,
βIII-tubulin
No No [68]
9 MIAMIcells P3-P9
cAMP, NT,
RA, SHH
1) bFGF. 2)
NT-3, SHH,
RA, FGF8. 3)
Forskolin,
NT-3, BDNF,
NGF, GDNF.
1) 24h. 2- 2
days. 3) 3-7
days
NSE, GFAP,
βIII-tubulin,
NF-L, NF-M,
Nurr1, TH
Inward Na+
currents and
outward K+
currents
No [69]
10 AT-MSCs ns
cAMP, NT,
RA, SHH
bFGF, IBMX.
2) SHH,RA.
3) BDNF,
GNDF
6 hours. 2) 1
week. 3) ns
βIII-tubulin,
ChAT, Nkx2.2,
Pax6, Hb9,
Olig2
No No [70]
11 UCB-MSCs P5-P8
cAMP-PKA,
NT, RA
RA, IBMX,
NGF, bFGF
8 hours to 7
days
GFAP, NF-L,
NF-M, NF-H,
NSE, Nurr-1,
TH, Tau
No H89 [60]
12 BM-MSCs P4
cAMP, PKC,
RA
Forskolin,
IBMX, TPA /
RA
Up to 48
hours / 7
days
βIII-tubulin,
GFAP, NSE, NF-
M
No No [71]
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Cell type Passage Pathways Inductionprotocol
Protocol
length
Neural
phenotype
Electro-
physiological
profile
Inhibitor Reference
13 BM-MSCs P3-P4
cAMP, RA
(RARβ)
1) RA. 2)
Forskolin
1) 24 hours.
2) ns
Nestin, NSE,
MAP2
Neuronal
resting
potential
No [72]
14 DP-SCs P0? RA
1) EGF,
bFGF. 2)
bFGF. 3)
bFGF, RA
1) 7 days. 2)
7 days. 3) 7
days.
Nestin, βIII-
tubulin, NF-M,
NFH, PSA-
NCAM
Inward Na+
currents No [41]
15 MIAMIcells P5-P9 cAMP, NT
1) EGF,
bFGF. 2)
bFGF. 3)
bFGF, NT-3.
4) 3)
Forskolin,
NT-3, BDNF,
NGF.
1) 10 days.
2) 24 hours.
3) 2 days. 4)
3 days
βIII-tubulin,
NF-M, NF-H,
NF-L, GalC
No No [73]
16 MIAMIcells ns
NT (TrkC)-
Rac1-
Mek1/2-
Erk1/2
1) bFGF. 2)
NT-3.
1) 24 hours.
2) 48 hours
βIII-tubulin,
NF-M, NF-H,
NF-L, Nestin
No
U0126,
K252a,
NSC23766
[74]
17 SKPs P3-P9 NT
1) bFGF,
EGF. 2)
NT-3, NGF,
BDNF
1) 2-3
weeks. 2)
2-3 weeks.
NF-M, GAP43,
βIII-tubulin,
MAP2
No No [37]
18 BM-NCSCs P5 clones MAPKs
Co-culture
with CGN 5 days βIII-tubulin
Inward Na+
currents and
outward K+
currents (PA
for BM-MSCs
clones)
PD98059 [43]
19 SKPs ns NT 1) bFGF,EGF. 2) NGF ns
NF-M, βIII-
tubulin, GFAP No No [75]
20 UCB-MSCs ns
NT-Raf1-
MAPK/ERK,
RA
bFGF, RA,
BDNF 7 days
βIII-tubulin,
NeuN, GFAP,
MBP
No LY294002,PD98059 [76]
21 UCB-MSCs ns
NT (TrkB)-
Raf1-MAPK-
ERK, B-
catenin
BDNF gene transfection
βIII-tubulin,
NeuN, GFAP,
MBP
No K252A [77]
22 WJ-MSCs P3 NT
BDNF /
HCNP /
rDHE
14 days MAP2, AChT No No [78]
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Cell type Passage Pathways Inductionprotocol
Protocol
length
Neural
phenotype
Electro-
physiological
profile
Inhibitor Reference
23 AT-MSCs ns cAMP-NT
1) bFGF,
EGF, BDNF.
2) IBMX
1) 3 days. 2)
48 hours
βIII-tubulin,
GFAP No No [79]
24
BM-
MSCs &
DP-SCs
P3 cAMP-NT bFGF, EGF,BDNF, IBMX 3-5 days.
GFAP, c-fos,
NF, HNK1,
enolase-2, βIII-
tubulin,
MAP2, Sox2,
Tenascin-C,
Connexin-43
and nestin
No No [80]
25 DP-SCs P1-P4 cAMP, PKC,RA
1) bFGF, 5-
azacytidine.
2) bFGF,
IBMX, TPA,
db-cAMP,
Forskolin,
NT-3, NGF.
3) db-cAMP,
NT-3.
1) 48 hours.
2) 3 days. 3)
3-7 days.
βIII-tubulin,
NF-M, GFAP,
NeuN, NSE
Inward Na+
currents and
outward K+
currents
No [81]
26 SKPs P3 NT, RA 1) RA. 2)NT-3
1) 7 days. 2)
7 days.
βIII-tubulin,
GFAP, MAP-2,
NeuN
No K252a,Pep5 [82]
27 SKPs ns cAMP, NT,RA
1) RA, NT-3,
BDNF, NGF,
db-cAMP
2 weeks to 1
month
PGP9.5, NF,
FMI-43,
NMDAR
No No [83]
29 BM-MSCs P3-P4
cAMP-
MAPK-MEK-
ERK-Raf
Forskolin 48 hours βIII-tubulin,NF200, NSE No PD98059 [58]
30 BM-MSCs ns
cAMP-PKA,
PKC, MAPK-
MEK-ERK
1) bFGF. 2)
Forskolin.
1)
Overnight.
2) Up to 7
days
NF No
K252a,
KT5720,
AG879,
KN-62,
LY294002,
PD98059
[57]
31 BM-MSCs P0? cAMP-Wnt
bFGF, IBMX,
Forskolin,
Wnt1
3 to 7 days
Ngn1, Brn3a,
NeuroD, P2X3,
GluR2, GluR4
No No [84]
(“ns” indicates that the passage or the incubation length are not specified. “No” indicates that no electrophysiological results
are described in the study or that no inhibitor has been tested to confirm the pathway). Hedgehog signaling pathway
Table 1. In vitro protocols for neural differentiation of different types of MSCs/NCSCs and detailed results.
Neural Fate of Mesenchymal Stem Cells and Neural Crest Stem Cells ...
http://dx.doi.org/10.5772/53260
337
The hedgehog-mediated signalization is involved in the embryonic development, and its
main ligand, Sonic Hedgehog (SHH) plays a role of morphogenic factor, defining which fate
has to be applied to cells at each place of the embryo: its role in the nervous system organi‐
zation is crucial and depends on precise concentration gradients which are essential for a
correct patterning of the embryo. Indeed, SHH signaling is the chief actor in the definition of
the dorsoventral axis of the nervous system. This signalization mostly takes place in cell cil‐
ia, and implies two different receptors that, once activated, generate a tricky reorganization
of cytoplasmic protein complexes. SHH binds its receptor Patched1 (Ptc), relieving Ptc-
mediated inhibition of a second receptor Smoothened (Smo): Ptc leaves the cilium where
Smo then accumulates and induces the activation of Gli family of transcription factors (Gli1,
Gli2, and Gli3) [85, 86].
SHH was used to induce dopaminergic differentiation of human BM-MSCs, as demonstrat‐
ed by Trzaska et al. After a 12-days incubation with SHH, coupled with fibroblast growth
factor 8 (FGF8) and basic fibroblast growth factor (bFGF), a great number of cells turned into
putative dopaminergic neurons, as showed by tyrosine hydroxylase (TH) expression and
electrophysiological features. Those cells showed higher expression of neuronal markers,
and downregulated genes which are involved in cell cycle regulation, like cyclin-dependent
kinase 2 (CDK2) and proliferating cell nuclear antigen (PCNA), indicating that they entered
a post-mitotic fate [65, 66].
Qi and al. analyzed the abilities of rhesus monkey BM-MSCs to differentiate into cholinergic
neural cells. While SHH alone in the culture medium did not trigger any modification of
resting potential, they demonstrated that BM-MSCs exhibited neuronal resting membrane
potential when retinoic acid (RA) was present in the culture medium, and under the combi‐
nation of both SHH and RA. Moreover, cells from the SHH+RA inducing group expressed
higher levels of synapsin and acetylcholine (ACh), indicating that the combination of both
signals was the best way to obtain cholinergic neurons [67].
Many other studies demonstrated a synergic role of SHH and RA in neural induction of BM-
MSCs. Kondo et al. identified those two signals as sensory factors, showing that SHH+RA
application leaded to the expression of glutamatergic sensory neuron markers (including
GATA3, Sox10 or GluR4) by treated BM-MSCs [68]. On the other hand, the combination of
SHH+RA added to FGF8 (before neurotrophin incubation) was showed to promote dopami‐
nergic fate in MIAMI cells [69], which expressed TH and other molecules involved in dopa‐
minergic differenciation, like Nurr1.
Human AT-MSCs were induced to neural differentiation through the action of SHH and
RA. After induction, immunochemical labeling showed βIII-tubulin, choline acetyltransfer‐
ase (ChAT), and NSE expression. The differentiated cells were then characterized by RT-
PCR and results showed that those cells were restricted to a ventral spinal fate (Nkx2.2,
Pax6, Hb9, and Olig2), suggesting that those cells could be good candidates for motoneur‐
ons generation, in the context of spinal cord injuries therapy [70].
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4.2. Retinoic acid signaling pathway
Retinoic acid (RA) is physiologically metabolized from retinol, thanks to the sequential ac‐
tion of cellular retinol-binding protein (CRBP), retinol dehydrogenase (RoDH) and retinal‐
dehyde dehydrogenases (RALDHs). Once in the cytoplasm, RA is bound by cellular RA-
binding protein (CRABP) and enters the nucleus to bind its specific receptors (RARs) and
the retinoid X receptors (RXRs), which themselves heterodimerize and bind to DNA sequen‐
ces known as the RAREs (RA-response elements). This activates transcription of target genes
(Hox genes, Oct4,...) [87]. This RA signalization is involved in brain development and more
particularly in the definition of the anterio-posterior axis of the nervous system, by regulat‐
ing the expression of Hox genes in defined localized domains of the embryo [88].
Whereas SHH was often coupled with RA in cell culture differentiation medium, the impli‐
cation of RA signaling in neuronal differentiation was also studied without a combination
with SHH. RA was demonstrated to act on the up-regulation of NF-L expression in UCB-
MSCs, while applied with IBMX, db-cAMP, nerve growth factor (NGF) and bFGF [60]. This
study also highlighted the role of RA and cAMP/PKA pathways in the differential phos‐
phorylation of TH during differentiation. Indeed, neurally differentiated cells express neu‐
ronal markers as Tau or NSE, whereas TH and Nurr-1 expression assessed their
dopaminergic profile.
In the study of Scintu et al., two different protocols were used to differentiate BM-MSCs into
neuronal cells. The first one was carried out by activating the cAMP and PKC pathway
(with forskolin, TPA and IBMX), whereas the second one consisted in RA treatment. Both
protocols leaded to NSE, βIII-tubulin, GFAP and NF positive cells [71].
Similarly, pre-treatment with RA before incubation with forskolin leaded BM-MSCs to ex‐
press higher levels of nestin, NSE, and microtubule associated protein 2 (MAP2) and exhibit
neural-like resting membrane potential and increased intracellular calcium concentration
[72]. They also demonstrated that only RA specific receptors RARa and RARc were ex‐
pressed in native BM-MSCs. Conversely, the expression of RARb was significantly increased
in differentiated neurons, suggesting its major role in neural differentiation.
Arthur et al. performed RA treatment of human DP-SCs, which subsequently showed neu‐
ral morphology and expression of βIII-tubulin, NF-M and NF-H, and more interestingly ex‐
hibited electrophysiological activity characteristic of sodium voltage-gated channels,
assessing for their potential ability to give rise to functional neurons [41].
4.3. Neurotrophic factors and downstream signaling pathways
Neurotrophins are secreted growth factors that are involved in the development of neurons
in the nervous system, as well as in their survival and functionality. This family of proteins
is constituted by the “prototypical” nerve growth factor (NGF), brain-derived growth factor
(BDNF), and the neurotrophins (NT-) 3, 4/5 and 6. Those members promote neural cells to
survive, grow, differentiate and function through the activation of high-affinity tyrosine-
kinase (tropomyosin-related) receptors (TrkA, TrkB and TrkC are respectively bound by
NGF/NT-6, BDNF/NT-4, and NT-3), and through the activation of a common low-affinity re‐
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ceptor, the p75LNR, which has no intrinsic kinase property. While p75LNR activation is suffi‐
cient to induce events like neurite formation, its role seems to facilitate the binding of
neurotrophins to Trk receptors. After trans-phosphorylation, Trk receptors function as acti‐
vators of three main signaling pathways, respectively mitogen-activated protein kinases
(MAPKs), phospholipase C (PLC) and phosphatidyl-inositol-3-kinase (PI3K) [89,90].
Briefly,  the  MAPKs  pathway  consists  in  a  set  of  sequentially-activated  kinase  proteins
grouped  in  three  main  connected  cascades,  involving  regulators  of  alpha-foetoproteins
(Raf), extracellular-regulated kinases (ERK), p38 or jun-kinase 1/2/3, resulting in the phos‐
phorylation  of  transcription  factors  and  then  regulating  gene  expression.  MAPKs  are
abundantly expressed in the central  nervous system (CNS),  and ERKs are known to be
involved  in  different  processes,  including  neuronal  maturation,  survival,  and  synaptic
functions.
The PLC signalization pathway mostly induces intracellular calcium mobilization, but fur‐
thermore stimulates protein kinase C (PKC) via the production of diacylglycerol (DAG). The
PKC can also be directly activated by 12-O-tetradecanoylphorbol-13-acetate (TPA), and is al‐
so able to activate MAPKs pathway.
Finally, PI3K controls another downstream kinase called Akt (also named protein kinase B
or PKB) that is a crucial player in cell survival through the regulation of apoptosis among
other roles.
Several additional neurotrophic factors are regrouped in a second family, the GDNF family
of ligands (GFL). Briefly, the glial neurotrophic factor (GDNF) is a protein that has been
shown to promote the survival and differentiation of dopaminergic neurons and motoneur‐
ons, and constitutes then an important potential actor in the management of neurological
diseases such as Parkinson’s disease [91, 92], amyotrophic lateral sclerosis or spinal cord in‐
juries. Neurturin, artemin and persephin are similar ligands that also play a role in cell sur‐
vival, neurite outgrowth, and cell differentiation migration. Those four members act by the
activation of a tyrosine kinase receptor RET, which in association with a co-receptor (GFRα),
triggers auto-transphosphorylation and downstream signaling processes.
A cocktail of the three main neurotrophins (BDNF, NGF and NT-3) was used to direct neu‐
ral differentiation of MIAMI cells, which began to develop a complex neuritic arborization
and to express neuronal markers, e.g. NF-L or NeuN [69]. Moreover, those differentiated
cells showed inward Na+ and outward K+ currents. This study also highlighted the impor‐
tance of NT-3 in the neural commitment and differentiation step, through the demonstration
of a dramatic decrease in viability, βIII-tubulin expression, neuron-like morphology and
branching of differentiated cells without NT-3 treatment. Those results were then further de‐
tailed and showed the enhanced neural specification from MIAMI cells thanks to epidermal
growth factor (EGF) and bFGF pre-treatment [73]; the implication of Rho-GTPase Rac1,
which was thought to regulate Mek1/2-Erk1/2 phosphorylation, mediating transcription of
genes involved in neural differentiation versus proliferation during NT-3-induced neuronal
commitment [74].
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The first assessment of the ability of SKPs to generate neural cells was achieved by the
group of Toma, who first described that about 9,4% of SKPs were NF-M, GAP43, βIII-tubu‐
lin and MAP2 positive after being treated with NGF, BDNF and NT-3 [37].
When co-cultivated with immature cerebellar granules, nestin-positive BM-MSCs are able to
differentiate into functional neuronal cells [93], as showed by βIII-tubulin expression and ac‐
tion potentials firings. After characterizing two subpopulations of BM-MSCs which were re‐
spectively derived and non-derived from the embryonic neural crest (after generating clonal
cultures), Wislet-Gendebien and collaborators demonstrated that the neural differentiation
of BM-NCSCs in co-culture conditions was abolished in the presence of a MAPKs inhibitor.
Those results confirmed the importance of MAPKs pathway in neural differentiation of
adult BM-NCSCs [43].
After adding NGF in the culture medium of human SKPs, Bakthiari et al. obtained NF-M,
βIII-tubulin, S100 and GFAP positive cells, and that after different conditions of cryopreser‐
vation [75].
Lim et al. demonstrated the important role of BDNF in neural differentiation of human
UCB-MSCs, and provided a deeper study of the different involved pathways. Addition of
BDNF in the induction medium leaded to the phosphorylation of Raf-1 and ERK, then to the
downstream up-regulation of p35 expression, which was not observed when ERK was
blocked with a specific inhibitor. p35 is known as an anti-apoptotic factor able to block pro‐
caspase maturation and to protect neurons from cell death [94, 95].
They also analyzed the contribution of BDNF to cell viability, and demonstrated an up-regu‐
lation of the anti-apoptotic gene Bcl2, which was mediated by the activity of PI3K and Akt
phosphorylation [76]. Few years later, after genetically modifying UCB-MSCs through trans‐
fection with a BDNF-expressing plasmid, they showed the expression of βIII-tubulin, NeuN,
GFAP and myelin basic protein (MBP) in differentiated cells, associated with an up-regulat‐
ed phosphorylation level of TrkB, Raf-1 and ERKs [77].
BDNF was also used to induce bi-multipolar morphology and MAP2 expression in WJ-
MSCs. When used in combination with hippocampal cholinergic neurostimulating peptide
(HCNP) and/or denervated hippocampal extract (rDHE), WJ-MSCs turned into Choline-ace‐
tyltransferase (ChAT) positive cells [96].
Coupled with IBMX, BDNF was able to induce GFAP and βIII-tubulin expression in AT-
MSCs, as demonstrated by Ying et al. [79]. The same combination of IBMX and BDNF was
used to differentiate DP-SCs into GFAP, c-fos, NF, HNK1, enolase-2, βIII-tubulin, MAP2,
Sox2, Tenascin-C, Connexin-43 and nestin positive cells [80].
Neural induction of DP-SCs was achieved by Kiraly et al. through the activation of both
cAMP and PKC signaling pathways. After reprogramming by 5-azacytidine treatment, cells
where treated with IBMX, db-cAMP, forskolin, TPA, NGF and NT-3, and showed an in‐
crease in neurogenin-2, βIII-tubulin, NSE, NF-M and GFAP expression, while electrophysio‐
logical recordings revealed voltage dependent sodium channels activity [81].
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The study of Zhang et al. demonstrated that RA induced SKPs to neural differentiation
through the up-regulation of the transcription factor NeuroD and the cell-cycle regulatory
protein p21 [82]. In the meantime, RA also induced p75NTR up-regulation that leaded to
apoptotic cell death. They showed that when treated with NT-3 after RA induction, the sur‐
vival and neural differentiation of SKPs were improved significantly, and cell apoptosis in‐
duced by RA was decreased. These effects were reversible as confirmed by the way of a
p75NTR inhibitor Pep5 instead of Trk receptor inhibitor K252a.
The three pathways of RA, cAMP and NT were recruited together to differentiate SKPs into
neuronal cells. After adding RA, db-cAMP, NGF, BDNF and NT-3 to the culture medium,
Lebonvallet et al. identified NF and PGP9.5 positive cells, which were also able to incorpo‐
rate FMI-43 staining, indicating the presence of synaptic vesicles. Furthermore, they showed
an overexpression of neuron-related genes in differentiated SKPs [83].
Kim et al. studied the involvement of non-neurotrophin-activated MAPKs pathway. They
showed that cAMP and PKA (resulting of forskolin treatment) promoted the phosphory‐
lation/activation of  B-Raf,  MEK and ERK [58].  Confirmation was specified with the  use
of an inhibitor of MAPKs pathway that induced a significant decrease in neural features
of forskolin-treated BM-MSCs. The same observation was carried out by Jori  et  al.,  con‐
firming that  neural-like  BM-MSCs reverted  to  uncommitted  cells  when cultured with  a
MEK-ERK inhibitor [57].
4.4. Wnt signaling pathway
The Wnt signaling pathway is constituted by a network of proteins that are involved in the
regulation of multiple developmental events during embryogenesis, but also in adulthood,
in several physiological processes and tissue homeostasis through cell fate specification, dif‐
ferentiation, or proliferation..
Wnt proteins act on cells by binding Frizzled (Fzd)/low density lipoprotein (LDL) recep‐
tor-related protein (LRP) receptor complex. When Wnt signal is inactive, the levels of cy‐
toplasmic  transcription  factor  β-catenin  are  kept  low  through  continuous  proteasome-
mediated  degradation,  which  is  regulated  by  a  complex  including  glycogen  synthase
kinase-3β (GSK-3), Axin, and Adenomatous Polyposis Coli (APC). Once Wnt ligands acti‐
vate Fzd/LRP, the degradation pathway is inhibited (through the activity of Dishevelled
(Dsh))  and β-catenin accumulates  in  the  cytoplasm.  After  nuclear  translocation,  it  inter‐
acts with T-cell specific transcription factors (TCF) among others, which allows transcrip‐
tion regulation [97, 98].
Kondo et al. exposed that BM-MSCs induced to neural differentiation (with forskolin and
IBMX) showed significant dose-dependent upregulation of sensory neurons markers Ngn1,
NeuroD, Brn3a and P2X3 when the induction medium was supplemented with recombinant
Wnt1 (whereas Wnt3a exhibited comparable but slighter effects)[84]. Glutamate receptors
GluR2 and GluR4 were also up-regulated in those conditions.
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5. Implications in cell therapy
With regards to their accessibility and their multipotentiality, adult and perinatal MSCs and
NCSCs constitute ideal stem cells to use in cell therapy. As it has been shown that those cells
could give rise to neuron-like cells via multiple ways of induction, we can infer that they
could be of valuable interest in the treatment of neurological lesions. In this paragraph, we
will collect the results of some studies that focused on cell therapy of Parkinson’s disease
and spinal cord injuries, using different types of MSCs/NCSCs and different ways to differ‐
entiate them into neurons before being transferred in animal models. Those results are sum‐
marized in the Table 2.
5.1. Dopaminergic neurons and Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alz‐
heimer’s disease, with a prevalence of 0,3% of the population in industrialized countries,
reaching 1% after 60 years of age [110]. This pathology is characterized by typical clinical
symptoms, like bradykinesia, rigidity, gait troubles and resting tremor, while the main
pathological feature is the loss of dopaminergic neurons in the Substantia Nigra pars com‐
pacta (SNpc), associated with ubiquitinated protein aggregates called Lewy bodies in differ‐
ent locations of the brain [111, 112].
In the last 80’s, clinical trials have been started, using fetal mesencephalic dopaminergic
neurons to transplant in PD patients [113, 114]. Despite the demonstration of several benefits
in terms of clinical symptoms and pathology, few problems remain. Fetal tissue heterogenei‐
ty, influence of harvesting methods on the graft efficiency, need of too much fetuses for only
one patient, altogether coupled with ethical concerns, left no option but finding other ways
to proceed. One of the main goals in this field relies in the replacement of lost dopaminergic
neurons in the nigrostriatal system, which could be achieved through the use of different
types of stem cells. As explained earlier, MSCs/NCSCs are interesting candidates in this ob‐
jective [115].
In this paragraph, we will review the results of some studies aiming to differentiate diverse
types of MSCs and NCSCs in dopaminergic neurons before grafting those cells in vivo, using
animal models mimicking the symptoms of PD (which are required to study the putative
usefulness of stem cells in regenerative therapy).
After in vitro differentiation of WJ-MSCs in dopaminergic neural cells using a SHH and
FGF8 treatment (in combination with brain-conditioned medium), Fu et al transplanted
those differentiated cells inside the striatum of hemiparkinsonian rats, previously treated
with 6-hydroxydopamine (6-OHDA). 20 days after transplantation, TH positive cells were
found around the implantation site, and those cells were shown to be grafted WJ-MSCs.
Moreover, the number of amphetamine-induced rotations (giving idea of motor performan‐
ces of hemiparkinsonian rats) was decreased, and this decrease was gradual over time,
showing an important improvement in the nigrostriatal pathway function [99].
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Cell type Differentiation protocol Animal model Histology Behavioral aspects Ref.
Dopaminergic neurons - Parkinson’s Disease
WJ-MSCs SHH, FGF8 (+ brain-conditioned medium) 6-OHDA rat
Survival after 20 days
TH positive grafted cells.
Decrease of
amphetamine-induced
rotations over time.
[99]
BM-MSCs SHH, FGF8, GDNF 6-OHDA rat Transient survivalNo differentiation No [100]
DP-SCs / SHED
Nothing 6-OHDA rat TH-positive grafted cells
Decrease of
apomorphine-induced
rotations over time. [101]
Forskolin, SHH, FGF8,
GDNF (in vitro)
In vitro expression of βIII-
tubulin, MAP2, and TH No
BM-MSCs Forskolin, IBMX, db-cAMP and TPA 6-OHDA rat
<4 weeks survival
Few TH expression
Many GABA positive cells
No [102]
Motoneurons - Spinal Cord Injuries
BM-MSCs 8-bromo-AMP andRolipram
Rat with
contused SC
A2B5, NCAM and B3T
positive cells
Recovery of hind limb
stepping and hind limb
weight support
[103]
BM-MSCs RA + NT-3 overexpressionRat withtransected SC
MAP2, NF and GFAP
positive cells
Reduction of cystic cavity
size
Rescue of surviving
neurons
Improvement of hindlim
locomotion [104]
BM-MSCs
Hb9 and Olig2
overexpression + RA,
forskolin, SHH
Injured
organotypic SC
slice
Integration in slice
ChAT positive cells No [105]
BM-MSCs RA, db-cAMP, forskolin,IBMX
Rat with
contused SC
In vitro expression of
MAP2, NSE, nestin, βIII-
tubulin
Reduced cystic cavity
Improvement in motor
performances [106]
UCB-MSCs Nothing
Rat with
hemisection SC
injury
Accumulation near the
lesion
Reduction of lesion size
Enhanced axon regrowth
Enhancement of
functional locomotor
abilities
[107]
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Cell type Differentiation protocol Animal model Histology Behavioral aspects Ref.
SKPs
Nothing Rat withcontused SC
Survival rate of
Reduced cavity size
Myelination of
endogenous axons
Recruitment of
endogenous Schwann
cells
Heightened sensory
responses
[108]
Forskolin (+
neuregulin-1β)
Rat with
contused SC
Survival rate of
Reduced cavity size
Myelination of
endogenous axons
Recruitment of
endogenous Schwann
cells
Bypass of the lesion
Reduced gliosis
Axonal growth
Increased BBB score and
Basso locomotor
subscore
Decease in the number
of hind limb errors
No impact of sensitivity
to sensory stimuli
EPI-NCSCs Nothing Rat withcontused SC
No migration, no
proliferation
Close contact with host
neuritis
βIII-tubulin, GAD67, RIP
and MBP positive cells.
No GFAP
No [109]
(“No” indicates that no behavioral testing is described in the study. Protocols describing in vitro differentiation in the
meantime than in vivo studies are also included in the table, as well as some in vivo studies using non-differentiated
cells).
Table 2. Different results obtained in cell-based therapy experiments using MSCs and NCSCs.
On the other hand, Khoo et al showed that neuronal-primed human BM-MSCs (with SHH,
FGF8, GDNF and other growth factors) did survive transiently in the brain of 6-OHDA-
treated rats, but no further differentiation in functional dopaminergic neurons was ob‐
served, even when a co-transplantation with olfactory ensheating cells (OECs) was
performed to enhance to graft efficiency [100].
The same cocktail was used by Wang et al. to differentiate SHED cells (DP-SCs) into dopa‐
minergic neurons, this time supplemented with forskolin. Differentiated cells were βIII-tu‐
bulin, MAP2 and TH positive in vitro. They further characterized naïve SHED cells by
transplanting them into the striatum of a hemiparkinsonian rat. While some TH-positive cell
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bodies were found in the graft zone, a significant decrease in apomorphine-induced rota‐
tions was observed, attesting of a beneficial effect of the cell transplantation [101].
cAMP pathway was recruited to differentiate BM-MSCs (after EGF/bFGF-induced sphere
formation) in dopaminergic neurons, using forskolin, IBMX and db-cAMP (coupled with the
PKC activator TPA) [102]. Differentiated cells showed in vitro expression of βIII-tubulin,
neurofilament, Nurr-1, TH, AADC and GIRK2. After transplantation into the striatum of 6-
OHDA rats, few cells were βIII-tubulin and TH positive, whereas a higher number of graft‐
ed cells became GABA-positive (maybe due to the striatal environment mainly composed of
GABA neurons). Unfortunately, no behavioral observation was described by Suon et al.
5.2. Motoneurons and spinal cord injuries
Whereas peripheral nerves are able to regenerate when a lesion occurs, the motoneurons
and nervous fibers in the spinal cord can’t be replaced in case of spinal cord injury (SCI).
Indeed, traumatic spinal cord injury results in a wide panel of pathophysiological events
counteracting any possibility of neural regeneration, and those events are generally grouped
in two phases. The primary injury phase can be due to either contusion or compression, and
is characterized by section of axons, necrosis, degeneration, oligodendrocytes apoptosis,
gliosis and macrophage infiltration. Altogether, those events lead to secondary lesions like
ischemia, inflammation, alteration of ion balance, insult of the blood-brain-barrier, lipid per‐
oxidation and glutamate-induced excitotoxicity. Despite a slight spontaneous recovery, all
those events collectively constitute an environment that hampers axonal regeneration [116].
Since the clinical consequences of such lesions are dramatic and rarely reversible (para-,
hemi-, tetraplegy, respiratory problems, loss of sphincters control, all leading to important
socio-economic issues), it’s crucial to find out efficient therapies to improve the recuperation
of motor function.
Stem cell grafting has been suggested as a therapeutic strategy for spinal cord repair, hence
the obtainment of mature motoneurons is critical.
Human BM-MSCs were induced to differentiate into neural cells through the activation of
cAMP signaling pathway, via the addition of 8-bromo-cAMP and Rolipram (inhibitor of
phosphodiesterases) in the culture medium. Those neurally-induced BM-MSCs were then
transplanted into a segment of the spinal cord of rats, previously wounded by contusion.
After confirming neural nature of differentiated cells by immunostaining of A2B5, NCAM,
B3T, in vitro as well as in vivo after transplantation, behavioral testing of rats revealed that
the motor recovery (assessed by hind limb stepping and weight support) was significantly
different at 2 to 12 weeks post-recovery in the group that was transplanted with neurally-
induced BM-MSCs when compared with the control groups that received non differentiated
BM-MSCs and saline solution [103].
Another protocol was tested by Zhang et al.,  who treated BM-MSCs with RA before ge‐
netically  modifying them to overexpress  the gene coding for  the neurotrophin 3  (NT-3)
[104].  Once they’ve showed that  RA pretreatment enhanced NT-3 expression and secre‐
tion by MSCs after genetic engineering, they transplanted cells into the transected spinal
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cord  of  rats.  Some  transplanted  cells  were  positive  for  MAP2,  NF  and  GFAP  labeling.
Moreover, cell transplantation leaded to the reduction of cystic cavity, improvement of lo‐
cal environment, rescue of surviving neurons from retrograde atrophy, and improvement
of hind limb locomotion.
Liqing et al. induced AT-MSCs to neural fate through the action of SHH and RA, and
showed that those cells expressed the transcription factors Nkx2.2, Pax6, Hb9, and Olig2,
suggesting those cells as attractive nominees to become mature motoneurons [70]. While no
in vivo testing has been performed in this study, another experiment focusing on ventral spi‐
nal-specific transcription factors was carried out by Park and al., who genetically modified
human BM-MSCs to express Hb9 and Olig2, just before treating them with neural induction
medium consisting in sequential incubation with RA, forskolin, SHH and FGF. In vitro,
those cells were excitable and were able to connect muscle fibers; while after transplantation
into an injured organotypic spinal cord slice culture, they survive and integrate the slice,
while expressing motoneurons-specific markers, e.g. ChAT [105].
Pedram et al. performed comparative study of the potencies of BM-MSCs to take part in the
repair of spinal cord damages, either when neurally-differentiated than when used in their
native state [106]. BM-MSCs were cultured following a multi-step protocol, in presence of
RA and bFGF, db-cAMP, forskolin and IBMX. After assessing the neural nature of differenti‐
ated cells (expression of MAP2, NSE, nestin, and βIII-tubulin), they transplanted cells into
the lesion cavity of contused rat spinal cords. Either undifferentiated BM-MSCs or neurally-
induced BM-MSCs transplantation leaded to a reduced cavity, but a significant improve‐
ment in motor performances was observed in rats that received neurally-differentiated BM-
MSCs (compared to control group and native BM-MSCs-transplanted group).
Obtaining myelinating glial cells is another way to manage spinal cord injuries. In that pur‐
pose, Biernaskie et al. studied the effect of SKPs on spinal cord lesions, when transplanted in
their naïve state or when pre-differentiated into Schwann cells (using forskolin and neure‐
gulin-1β) [108]. They showed that a graft of both the naïve SKPs and SKPs-derived Schwann
cells leaded to a reduced cystic cavity size, and that the cells myelinated host axons and re‐
cruited host Schwann cells. Still, the SKPs-derived Schwann cells were the only ones to gen‐
erate a bridge across the lesion and to induce a growth-permissive environment, while a
substantial improvement was observed at the behavioral level (Increased BBB score and Bas‐
so locomotor subscore and decrease in the number of hind limb errors).
Significant enhancement of functional locomotor abilities was observed by Schira et al. af‐
ter transplantation of unrestricted UCB-MSCs into the surrounding area of a hemisection
injury,  accompanied  by  cell  accumulation  near  the  lesion,  reduction  in  its  size  and en‐
hanced axon regrowth [107]. This study gives an example of what can be observed using
naïve stem cells in cell therapy, without any pre-differentiation. In the same way, Sieber-
Blum et al. transplanted EPI-NCSCs in the core of a spinal cord lesion, and observed βIII-
tubulin,  GAD67,  RIP  and MBP positive  cells  among the  grafted  cells.  Those  cells  were
tightly close to endogenous neuritis, but did not show any sign of proliferation nor migra‐
tion in the tissue [109].
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6. Conclusions
Mesenchymal  stem  cells  (MSCs)  and  neural  crest  stem  cells  (NCSCs)  are  multipotent
cells  that  are  able  to  generate  a  wide  range  of  cell  types,  including neural  cells,  which
makes  them  incredibly  interesting  in  restorative  therapies  for  patients  suffering  from
neurological diseases. A lot of induction protocols indicate that many signaling pathways
may be involved in the neural fate of MSCs and NCSCs. Indeed, the signalization path‐
ways of cAMP, Retinoic acid, Hedgehog, Wnt and the neurotrophins-activated pathways
have been implicated into the maturation of adult MSCs/NCSCs into neural-like cells. Af‐
ter  an  induction process  consisting  in  various  activators,  lengths  and conditions  of  cul‐
ture, treated cells adopt a neural morphology express markers (at the transcriptome level
as well as at the protein level) that are usually described to characterize neurons at dif‐
ferent developmental stages [117, 118] in MSCs as well as in NCSCs. Despite the expres‐
sion of those specific neural markers, only a tiny number of in vitro  protocols were able
to provide convincing evidence for a neuron-specific electrophysiological signature of the
differentiated cells.
During neural  development,  immature neural  cells  undergo a differentiation process to‐
wards functional neurons through different stages that are accurately defined by specific
electrophysiological  features.  Briefly,  the  first  currents  that  occur  in  the  cell  consist  in
voltage-dependent outward potassium currents. As maturation proceeds, voltage-depend‐
ent  inward calcium and sodium currents  arise  sequentially.  The  ultimate  step is  finally
characterized by the elicitation of action potential through the activity of several mature
voltage-gated sodium channels: an important depolarization triggers intracellular modifi‐
cations,  proteins activation, and vesicular trafficking that are required for proper synap‐
tic chemical and electrical function/transmission [119-121]. As clearly observed in Table 1,
even if a few data attest of electrophysiological activity in MSCs/NCSCs-derived neuron-
like cells (as showed by sodium and potassium currents),  there is no sufficient evidence
for action potential firings and for an appropriate neuronal function.
As  showed  by  the  diagram  on  the  figure  3,  most  of  the  collected  studies  describe  the
cAMP  signaling  pathway  to  play  a  key  role  in  the  neural  differentiation  of  MSCs/
NCSCs.  On  the  other  hand,  neurotrophins  are  often  used  for  neural  differentiation,
whereas  MAPKs  have  been  shown  to  be  involved  too.  RA  represents  the  third  most
used  signaling  molecule.  We  can  see  that  the  most  part  of  studies  showing  significant
electrophysiological  recordings use RA treatment for  differentiation,  suggesting its  note‐
worthy role  in  this  process  (16,1  % of  the total  number of  studies  (5/31)  and 62,5  % of
the  number  of  studies  showing  significant  electrophysiological  recordings  (5/8)).  Addi‐
tionally,  a  major  number  of  protocols  were  performed in  association  with  cAMP path‐
way  activation.  On  the  other  hand,  40%  of  the  differentiation  protocols  using  SHH
signalization (2/5 studies) were able to induce changes in electrical activity (see Table 1).
That presumably raises the question of a role for RA and SHH in the last stages of ma‐
turation of MSCs/NCSCs into neural-like cells.
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Figure 3. Percentages of differentiation protocols involving cAMP, RA or neurotrophins/MAPKs signaling pathways
among the 31 detailed studies. Percentages are expressed in regard to the total number of studies. Numbers in red
indicate the percentages of studies describing significant electrophysiological recordings.
Overall, we tend to conclude that although the cells express neural-specific proteins and ex‐
hibit a preliminary electrical activity [122, 123], MSCs and NCSCs do not seem to be able to
fully differentiate and generate functional neurons in order to reach the objective of cell-
based therapy in human neurological treatments.
However, several in vivo studies based on MSCs/NCSCs-derived neural cells demonstrate a
significant improvement of symptoms and lesions in animal models of neurological disor‐
ders, such as Parkinson’s disease or spinal cord injury [24]. In these studies, the transplanta‐
tion of differentiated MSCs/NCSCs leads to the limitation of the lesions and the recovering
of motor functions. Regarding other successful cell therapy experiments based on the trans‐
plantation of non-differentiated MSCs/NCSCs, we can infer that the experimental enhance‐
ment is more likely to be due to the intrinsic properties of the grafted cells, and not to a
genuine differentiation process nor to an authentic neuronal electrical activity. Indeed, even
if their ability to generate neurons is present but quite limited, they still display important
immunomodulatory and anti-inflammatory properties, they secrete a lot of growth and neu‐
rotrophic factors, they modulate apoptosis processes, and promote endogenous precursors
recruitment [124-128]
In conclusion, those observations confirmed the significance of MSCs and NCSCs use in cell
therapy procedures to treat several neurological disorders, sustaining their high capacity to
protect or restore neural tissue through many proceedings that are probably more owed to
intrinsic abilities than to neuronal differentiation.
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